Dot Therapeutics2 receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Day One Biopharmaceuticals Inc (DAWN)
Day One Biopharmaceuticals Inc stock price live, this page displays NASDAQ DAWN stock exchange data. View the DAWN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Day One Biopharmaceuticals Inc real time stock price chart below.
What Is the Day One Biopharmaceuticals Inc Stock Price Today?
The Day One Biopharmaceuticals Inc stock price today is 11.37.
What Is the Stock Symbol for Day One Biopharmaceuticals Inc?
The stock symbol for Day One Biopharmaceuticals Inc is ""DAWN.""
What Stock Exchange Does Day One Biopharmaceuticals Inc Trade On?
Day One Biopharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Day One Biopharmaceuticals Inc a Good Stock to Buy?
Determining whether Day One Biopharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DAWN quote. (ISIN: US23954D1090)
What Is the Day One Biopharmaceuticals Inc Stock Price Today?
The Day One Biopharmaceuticals Inc stock price today is 11.37.
What Is the Stock Symbol for Day One Biopharmaceuticals Inc?
The stock symbol for Day One Biopharmaceuticals Inc is ""DAWN.""
What Stock Exchange Does Day One Biopharmaceuticals Inc Trade On?
Day One Biopharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Day One Biopharmaceuticals Inc a Good Stock to Buy?
Determining whether Day One Biopharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DAWN quote. (ISIN: US23954D1090)
11.37
-0.41(-3.48%)
Real-time Data·
Fair Value
An estimate of a Day One Biopharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.28
12.15
52 wk Range
5.64
13.20
DAWN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Day One Biopharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.2812.15
52 wk Range
5.6413.20
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DAWN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Day One Biopharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
23.56
Upside
+107.17%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Day One Biopharmaceuticals Inc Company Profile
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Day One Biopharmaceuticals Inc Earnings Call Summary for Q3/2025
- Day One Biopharmaceuticals reported Q3 2025 EPS of -$0.19 (beating -$0.29 forecast) and revenue of $39.8M (exceeding $38.19M forecast), despite stock declining 0.14% in regular trading.
- The company raised full-year 2025 revenue guidance to $145-$150M following a 15% quarter-over-quarter increase in net product revenue to $38.5M, driven by OJEMDA's commercial success.
- Key operational achievements include an 18% increase in total prescriptions and 20% rise in new patient starts, with OJEMDA revenue exceeding combined cost of sales and SG&A for the first time.
- Despite positive performance, the stock remains near its 52-week low of $5.64, reflecting investor caution amid broader market conditions affecting the biotech sector.
- The company maintains a strong financial position with $451.6M in cash reserves and no debt, while focusing on pipeline advancement and establishing OJEMDA as a standard of care.
Last Updated: 04/11/2025, 23:48
Read Full TranscriptCompare DAWN to Peers and Sector
Metrics to compare | DAWN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDAWNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.7x | −1.9x | −0.6x | |
PEG Ratio | 0.14 | 0.05 | 0.00 | |
Price/Book | 2.6x | 2.3x | 2.6x | |
Price / LTM Sales | 8.8x | 85.8x | 3.4x | |
Upside (Analyst Target) | 112.2% | 86.7% | 43.4% | |
Fair Value Upside | Unlock | 23.4% | 6.3% | Unlock |
Analyst Ratings
9 Buy
1 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 23.56
(+107.17% Upside)
Earnings
Latest Release
Nov 04, 2025
EPS / Forecast
-0.19 / -0.29
Revenue / Forecast
39.80M / 38.19M
People Also Watch
FAQ
What Stock Exchange Does Day One Biopharmaceuticals Trade On?
Day One Biopharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Day One Biopharmaceuticals?
The stock symbol for Day One Biopharmaceuticals is "DAWN."
What Is the Day One Biopharmaceuticals (DAWN) Afterhours Price Today? (Afterhours variable test: 11.80) Current Date: 29 Jan 2026
After hours price: 11.80. After hours price change (units): 0.02. Price change percentage: 0.17%
What Is the Day One Biopharmaceuticals Market Cap?
As of today, Day One Biopharmaceuticals market cap is 1.17B.
What Is Day One Biopharmaceuticals's Earnings Per Share (TTM)?
The Day One Biopharmaceuticals EPS (TTM) is -1.47.
When Is the Next Day One Biopharmaceuticals Earnings Date?
Day One Biopharmaceuticals will release its next earnings report on 08 Mar 2026.
From a Technical Analysis Perspective, Is DAWN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Day One Biopharmaceuticals Stock Split?
Day One Biopharmaceuticals has split 0 times.
How Many Employees Does Day One Biopharmaceuticals Have?
Day One Biopharmaceuticals has 184 employees.
What is the current trading status of Day One Biopharmaceuticals (DAWN)?
As of 29 Jan 2026, Day One Biopharmaceuticals (DAWN) is trading at a price of 11.37, with a previous close of 11.78. The stock has fluctuated within a day range of 11.28 to 12.15, while its 52-week range spans from 5.64 to 13.20.
What Is Day One Biopharmaceuticals (DAWN) Price Target According to Analysts?
The average 12-month price target for Day One Biopharmaceuticals is USD23.56, with a high estimate of USD34 and a low estimate of USD16. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +107.17% Upside potential.
What Is the DAWN After Hours Price?
DAWN's last after hours stock price is 11.80, the stock has decreased by 0.02, or 0.17%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.